

Ref: FOI/GS/ID 6660

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

24 May 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Rheumatology.

You asked:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- a. Abatacept [Orencia]*
- b. Adalimumab [Humira]*
- c. Adalimumab Biosimilars*
- d. Apremilast [Otezla]*
- e. Baricitinib [Olumiant]*
- f. Certolizumab [Cimzia]*
- g. Etanercept [Enbrel]*
- h. Etanercept Biosimilars*
- i. Filgotinib [Jyseleca]*
- j. Golimumab [Simponi]*
- k. Infliximab [Remicade]*
- l. Infliximab Biosimilars*
- m. Ixekizumab [Taltz]*
- n. Rituximab [MabThera]*
- o. Rituximab Biosimilars*
- p. Sarilumab [Kevzara]*
- q. Secukinumab [Cosentyx]*
- r. Tocilizumab [Ro Actemra]*
- s. Tofacitinib [Xeljanz]*
- t. Upadacitinib [Rinvoq]*
- u. Ustekinumab [Stelara]*

Q2. Could you please provide the numbers of patients treated for Rheumatoid Arthritis ONLY in the last 3 months with the following drugs:

- a. *Abatacept [Orencia]*
- b. *Adalimumab [Humira]*
- c. *Adalimumab Biosimilars*
- d. *Baricitinib [Olumiant]*
- e. *Certolizumab [Cimzia]*
- f. *Etanercept [Enbrel]*
- g. *Etanercept Biosimilars*
- h. *Filgotinib [Jyseleca]*
- i. *Golimumab [Simponi]*
- j. *Infliximab [Remicade]*
- k. *Infliximab Biosimilars*
- l. *Rituximab [MabThera]*
- m. *Rituximab Biosimilars*
- n. *Sarilumab [Kevzara]*
- o. *Tocilizumab [Ro Actemra]*
- p. *Tofacitinib [Xeljanz]*
- q. *Upadacitinib [Rinvoq]*

Trust response:

Please note: Figures are for January, February and March 2021.

1.

- a. 68
- b. 89
- c. 237
- d. 1
- e. 15
- f. 30
- g. 22
- h. 216
- i. Not used
- j. 112
- k. 11
- l. 31
- m. 1
- n. 1
- o. 17
- p. 3
- q. 74
- r. 67
- s. 28
- t. Not used
- u. 7

2.

- a. 68
- b. 35
- c. 104
- d. 15
- e. 20
- f. 12
- g. 135

| | |
|----|----------|
| h. | Not used |
| i. | 29 |
| j. | 6 |
| k. | 13 |
| l. | 1 |
| m. | 15 |
| n. | 3 |
| o. | 84 |
| p. | 22 |
| q. | Not used |